FDA Approves KISQALI (ribociclib) Product Under Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product redeeming a priority review voucher for KISQALI (ribociclib), a treatment for rare pediatric diseases, following a review of its supplemental application.